- Home
- GDEV vs CUE Comparison
GDEV vs CUE Comparison
Compare GDEV & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEV | CUE |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 233.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GDEV | CUE |
|---|---|---|
| Price | $10.98 | $28.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 1.5K | ★ 158.0K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $8.05 | N/A |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $10.00 | $0.17 |
| 52 Week High | $42.20 | $45.50 |
Technical Indicators
Market Signals| Indicator | GDEV | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 49.94 |
| Support Level | $11.64 | $24.35 |
| Resistance Level | $12.00 | $32.50 |
| Average True Range (ATR) | 0.38 | 3.04 |
| MACD | 0.09 | 0.35 |
| Stochastic Oscillator | 88.00 | 56.84 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.